Literature DB >> 2541099

Prognosis of testicular tumour since the introduction of complex therapy.

D Frang1, L Farkas, F Götz, J Székely.   

Abstract

Change of approach in dealing with testicular carcinoma has made it necessary to set up a central organization covering a larger geographic area in Hungary where 242 patients had been treated since 1980. Progress in the development of therapy-oriented methods cleared the way for reliable and accurate stage determination. Data analysis seems to indicate that correct therapeutic principles combined with plenty of surgical, radiological and chemotherapeutic experience may contribute a lot to improving the pathologic prospects. The mortality rates for the pure seminoma group and for the non-seminomatous plus mixed-cell group of patients were 7.5% and 26.5%, respectively. The results promise additional chances--even with increasing morbidity--to reduce the mortality rate and the incidence of complications.

Entities:  

Mesh:

Year:  1989        PMID: 2541099     DOI: 10.1007/bf02549905

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  20 in total

1.  Management of testicular tumors.

Authors:  W J STAUBITZ; I V MAGOSS; O J OBERKIRCHER; M H LENT; F D MITCHELL; W T MURPHY
Journal:  J Am Med Assoc       Date:  1958-02-15

2.  [Significance of radiologic examinations for the determination of the extent of malignant testicular tumors].

Authors:  E Kuhn; K Böhm; Z Molnár; Z Than; G Varga
Journal:  Strahlentherapie       Date:  1975-11

3.  Testicular germ cell tumours--a model for a new approach to treatment of adult solid tumours.

Authors:  R T Oliver
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

Review 4.  Pathology of germ cell tumors of testis: a progress report.

Authors:  F K Mostofi
Journal:  Cancer       Date:  1980-04-15       Impact factor: 6.860

5.  Seminoma at Roswell Park, 1970 to 1979. An analysis of treatment failures.

Authors:  R P Huben; P D Williams; J E Pontes; A M Panahon; G P Murphy
Journal:  Cancer       Date:  1984-04-01       Impact factor: 6.860

6.  Complications of retroperitoneal lymph node dissection.

Authors:  J P Donohue; R G Rowland
Journal:  J Urol       Date:  1981-03       Impact factor: 7.450

7.  The management of metastatic seminoma testis.

Authors:  D Ball; A Barrett; M J Peckham
Journal:  Cancer       Date:  1982-12-01       Impact factor: 6.860

8.  The role of surgery in the combined management of metastases from malignant teratomas of testis.

Authors:  W F Hendry; A Barrett; T J McElwain; D M Wallace; M J Peckham
Journal:  Br J Urol       Date:  1980-02

Review 9.  The management of nonseminomatous testicular cancer: current therapy and future directions.

Authors:  S S Ostrow
Journal:  Am J Med Sci       Date:  1983 Jan-Feb       Impact factor: 2.378

10.  Primary lymphadenectomy or primary chemotherapy in advanced metastatic testicular tumor?

Authors:  N Jaeger; L Weissbach; J E Altwein; E Kreuser
Journal:  Eur Urol       Date:  1983       Impact factor: 20.096

View more
  1 in total

1.  Is modified retroperitoneal lymph node dissection (MRLND) still feasible in the treatment of patients with clinical stage I non-seminomatous testicular cancer?

Authors:  M Sosnowski; L Jeromin; A Płuzańska
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.